News >

Optimizing Genetic Testing Remains Challenge in Hematologic Malignancies

Caroline Seymour
Published: Wednesday, Feb 28, 2018

DNA The scope of genetic testing continues to evolve, yet in hematologic malignancies, Andrew Laramore, MD, says that it is difficult to determine which patients should be tested and how panels should be best utilized.

“Nobody has a clear-cut answer as to whether everybody should get tested, or whether it should be done on a case-by-case basis, said Laramore, a pathologist at Diagnostic Pathology Services.

While genetic tests on patients with chronic myeloid leukemia (CML) may be positive for BCR-ABL1, a molecular driver for the disease, there are other mutations that may show up on panels in which practitioners are unsure if they are related to the disease or not, he added.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication